{"id":"NCT03739684","sponsor":"Progenics Pharmaceuticals, Inc.","briefTitle":"Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer","officialTitle":"A Phase 3, Multi-Center, Open-Label Study to Assess the Diagnostic Performance and Clinical Impact of 18F-DCFPyL PET/CT Imaging Results in Men With Suspected Recurrence of Prostate Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-11-27","primaryCompletion":"2019-08-29","completion":"2019-08-29","firstPosted":"2018-11-14","resultsPosted":"2021-06-14","lastUpdate":"2021-06-14"},"enrollment":208,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"DIAGNOSTIC"},"conditions":["Prostate Cancer","Prostate Adenocarcinoma","Prostate Cancer Recurrent","Prostate Cancer Metastatic"],"interventions":[{"type":"DRUG","name":"18F-DCFPyL","otherNames":["PyL"]},{"type":"DIAGNOSTIC_TEST","name":"PET/CT Imaging","otherNames":[]}],"arms":[{"label":"18F-DCFPyL Injection","type":"EXPERIMENTAL"}],"summary":"This study evaluates the diagnostic performance and safety of 18F-DCFPyL (PyL) PET/CT imaging in patients with suspected recurrence of prostate cancer who have negative or equivocal findings on conventional imaging.","primaryOutcome":{"measure":"Correct Localization Rate (CLR)","timeFrame":"Within 60 days following 18F-DCFPyL PET/CT imaging.","effectByArm":[{"arm":"18F-DCFPyL Injection","deltaMin":85.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":5},"locations":{"siteCount":14,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":208},"commonTop":["Headache","Fatigue","Hypertension"]}}